{
    "clinical_study": {
        "@rank": "131311", 
        "arm_group": [
            {
                "arm_group_label": "BF-200 ALA", 
                "arm_group_type": "Active Comparator", 
                "description": "Topical application of BF-200 ALA gel containing 78 mg/g 5-aminolevulinic acid. Application of a 1 mm thick layer covering each lesion  and 0.5 to 1 cm of surrounding margin."
            }, 
            {
                "arm_group_label": "methyl-aminolevulinate", 
                "arm_group_type": "Active Comparator", 
                "description": "Topical application of Metvix creme containing 160 mg/g methyl-aminolevulinate. Application of a 1 mm thick layer covering each lesion  and 0.5 to 1 cm of surrounding margin."
            }
        ], 
        "brief_summary": {
            "textblock": "The aim of this study is to test the effectiveness and safety of the medicine Ameluz\u00ae, used\n      with photodynamic therapy (PDT), to treat thin, non-aggressive rodent ulcer."
        }, 
        "brief_title": "Safety and Efficacy Study for the Treatment of Non-Aggressive Basal Cell Carcinoma With Photodynamic Therapy", 
        "completion_date": {
            "#text": "October 2019", 
            "@type": "Anticipated"
        }, 
        "condition": "Basal Cell Carcinoma (BCC)", 
        "condition_browse": {
            "mesh_term": [
                "Carcinoma", 
                "Carcinoma, Basal Cell"
            ]
        }, 
        "detailed_description": {
            "textblock": "The treatment comprises of up to 2 PDT cycles, each with two PDT sessions one week apart.\n\n      If 12 weeks after the the second PDT all lesions are completely cleared the patient will\n      enter the follow-up phase. In case of remaining lesions the patient will receive a second\n      PDT cycles starting on the same day."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Willing and able to sign the informed consent form; must be obtained in writing for\n             all patients before starting any study procedures.\n\n          -  Presence of 1to 3 thin (\u22642 mm thickness), non-aggressive, primary BCC lesions\n             (comprising primary superficial, nodular, or mixed superficial/nodular) in the\n             face/forehead, bald scalp, extremities and/or neck/trunk. Confirmation of\n             non-aggressiveness and thickness of BCC through biopsies of all lesions taken at\n             screening.\n\n          -  The diameter of each lesion should range between \u2265 0.5 cm and \u22642 cm; the total\n             maximal treated area is approximately 10 cm\u00b2 (including a 0.5 - 1.0 cm margin\n             surrounding each lesion). The maximal thickness of a lesion should not exceed 2 mm\n             (by means of histopathological confirmation).\n\n          -  Target BCC lesions must be discrete and quantifiable and have to be located within\n             1-2 treatment areas.\n\n          -  Free of significant physical abnormalities (eg tattoos, dermatoses) in the potential\n             treatment area that may cause difficulty with examination or final evaluation.\n\n          -  Accept to abstain from extensive sunbathing and the use of a solarium during the\n             observer blind part of the study. Patients with sunburn within the treatment areas\n             cannot be included until fully recovered.\n\n          -  Healthy patients and patients with clinically stable medical conditions, including,\n             but not limited to controlled hypertension, diabetes mellitus type II,\n             hypercholesterolemia, and osteoarthritis, will be permitted to be included in the\n             study if their medication is not prohibited by this protocol.\n\n          -  Women of childbearing potential are permitted to participate in this study only if\n             they have a negative serum pregnancy test at screening and a willingness to use a\n             highly effective method of contraception during the observer blind part of the study.\n\n        Exclusion Criteria:\n\n          -  History of hypersensitivity to 5-ALA or any ingredient of BF-200 ALA, MAL or any\n             ingredient of Metvix\u00ae cream, including arachis oil, or to peanut or soya.\n\n          -  Hypersensitivity to porphyrins.\n\n          -  Current treatment with immunosuppression therapy.\n\n          -  Presence of porphyria.\n\n          -  Presence of BCC lesions on embryonic fusion planes (H-zone).\n\n          -  Presence of more than 3 BCCs.\n\n          -  Presence of malignant or benign tumors or precancerous lesions of the skin other than\n             nonaggressive BCC within the treatment area (eg malignant melanoma, squamous cell\n             carcinoma (SCC)) within the last 12 weeks.\n\n          -  Gorlin Syndrome or Xeroderma pigmentosum.\n\n          -  Presence of photodermatoses.\n\n          -  Treatment of lesions (actinic keratosis (AK), BCC, SCC, Bowens disease, melanoma) \u226412\n             weeks prior to first PDT, except physical treatments (eg cryosurgery, excision\n             surgery) that will not be allowed \u22644 weeks prior to screening visit (Visit 1).\n\n          -  Presence of inherited or acquired coagulation defect.\n\n          -  Start of intake of medication with hypericin or systemically-acting drugs with\n             phototoxic or photoallergic potential within 8 weeks prior to screening.\n\n          -  Clinically relevant cardiovascular, hepatic, renal, neurologic, endocrine, or other\n             major systemic disease making implementation of the protocol or interpretation of the\n             study results difficult.\n\n          -  Evidence of clinically significant (CS), unstable medical conditions, such as:\n\n               -  Metastatic tumor or tumor with high probability of metastasis.\n\n               -  Cardiovascular disease (New York Heart Association [NYHA] class III, IV).\n\n               -  Immunosuppressive condition.\n\n               -  Hematologic, hepatic, renal, neurologic, or endocrine condition.\n\n               -  Collagen-vascular condition.\n\n               -  Gastrointestinal condition.\n\n          -  Topical treatment with 5-ALA or MAL outside the treatment area during the observer\n             blind part of the study.\n\n          -  Any topical treatment including diclofenac and immunomodulatory agents (eg imiquimod,\n             ingenol mebutate) 12 weeks prior to the first PDT session and during the observer\n             blind part of the study.\n\n          -  Any physical treatment during the observer blind part of the study within the treated\n             target areas."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "360", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 20, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02144077", 
            "org_study_id": "ALA-BCC-CT008", 
            "secondary_id": "2013-003241-42"
        }, 
        "intervention": [
            {
                "arm_group_label": "BF-200 ALA", 
                "description": "topical treatment for photodynamic therapy combining drug application and subsequent illumination with a narrow spectrum light source (after 3 h of drug incubation)", 
                "intervention_name": "BF-200 ALA", 
                "intervention_type": "Drug", 
                "other_name": "Ameluz"
            }, 
            {
                "arm_group_label": "methyl-aminolevulinate", 
                "description": "topical treatment for photodynamic therapy combining drug application and subsequent illumination with a narrow spectrum light source (after 3 h of drug incubation)", 
                "intervention_name": "methyl-aminolevulinate", 
                "intervention_type": "Drug", 
                "other_name": "Metvix"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Aminolevulinic Acid", 
                "Methyl 5-aminolevulinate"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Photodynamic Therapy", 
            "PDT", 
            "non-aggressive BCC"
        ], 
        "lastchanged_date": "May 19, 2014", 
        "location": {
            "contact": {
                "email": "Rolf-Markus.Szeimies@Klinikum-Vest.de", 
                "last_name": "Rolf-Markus Szeimies, Prof. Dr."
            }, 
            "facility": {
                "address": {
                    "city": "Recklinghausen", 
                    "country": "Germany", 
                    "state": "Westfalen-Lippe", 
                    "zip": "45657"
                }, 
                "name": "Klinikum Vest GmbH"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Germany"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Randomized, Observer Blind, Multinational Phase III Study to Evaluate the Safety and Efficacy of BF-200 ALA (Ameluz\u00ae) in Comparison to Metvix\u00ae in the Treatment of Non-aggressive Basal Cell Carcinoma (BCC) With Photodynamic Therapy (PDT)", 
        "overall_official": [
            {
                "affiliation": "Klinik fuer Dermatologie und Allergologie (Klinikum Vest - Knappschaftskrankenhaus), Recklinghausen, Germany", 
                "last_name": "Rolf M. Szeimies, Prof. Dr.", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Dermatology Department, Stirling Community Hospital, NHS Forth Valley, United Kingdom", 
                "last_name": "Colin Morton, Dr.", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "Germany: Federal Institute for Drugs and Medical Devices", 
                "United Kingdom: Medicines and Healthcare Products Regulatory Agency", 
                "United Kingdom: Research Ethics Committee"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "January 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Complete responder rate at week 12 after last PDT", 
            "measure": "Patient complete response rate", 
            "safety_issue": "No", 
            "time_frame": "12 weeks after the last PDT"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02144077"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Lesion complete response (completely cleared individual lesions) assessed 12 weeks after the last PDT", 
                "measure": "Lesion complete response", 
                "safety_issue": "No", 
                "time_frame": "12 weeks after the last PDT"
            }, 
            {
                "description": "Reduction of total lesion area (summation of sizes of all treated lesions) per patient, assessed 12 weeks after the last PDT.", 
                "measure": "Reduction of lesion area", 
                "safety_issue": "No", 
                "time_frame": "12 weeks after the last PDT"
            }, 
            {
                "description": "Patient complete response (complete clearance of all treated lesions) assessed 12 weeks after PDT-2 (first PDT cycle).", 
                "measure": "Patient complete response", 
                "safety_issue": "No", 
                "time_frame": "12 weeks after the last PDT"
            }, 
            {
                "description": "Overall cosmetic outcome 12 weeks after last PDT", 
                "measure": "Overall cosmetic outcome", 
                "safety_issue": "No", 
                "time_frame": "12 weeks after the last PDT"
            }, 
            {
                "description": "Frequency and extent of treatment-emergent AEs (TEAEs), including serious AEs (SAEs).\nTEAEs are defined as all AEs with onset or worsening after first treatment with randomized investigational medicinal product (IMP).", 
                "measure": "Number of Participants with Adverse Events as a Measure of Safety and Tolerability", 
                "safety_issue": "Yes", 
                "time_frame": "up to 12 weeks after the last PDT for the observer-blind study"
            }, 
            {
                "description": "Local skin reactions in the treatment area as assessed by the investigators during illumination.", 
                "measure": "Local skin reactions", 
                "safety_issue": "Yes", 
                "time_frame": "during and up to 7 days after each PDT"
            }, 
            {
                "description": "Local discomfort or pain reported by patients during illumination.", 
                "measure": "Local discomfort", 
                "safety_issue": "Yes", 
                "time_frame": "during and up to 7 days after PDT"
            }
        ], 
        "source": "Biofrontera Bioscience GmbH", 
        "sponsors": {
            "collaborator": {
                "agency": "Accovion GmbH", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "Biofrontera Bioscience GmbH", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "January 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}